fashion -WSS

fashion

author：hotspot 2025-10-01 12:34:56 - browse：949

A woman walks in San Francisco, with her father who has Alzheimer's – public health and science coverage from STAT — Ben Margot/AP

A host of hurdles are slowing the adoption of the new Alzheimer’s drug Leqembi, experts involved in the treatment of patients said Wednesday, from complicated logistics to the fact that many people don’t recognize that their memory loss is a disease soon enough.

Some patients still grapple with whether they want to be diagnosed, even though a treatment exists, the experts said, speaking during a STAT virtual event.

“Even the word for dementia does not always exist in every culture and in every language,” said Hollis Day, chief of geriatrics at Boston Medical Center and a professor at Boston University’s medical school. “And so just getting people to accept that memory loss is not normal aging necessarily, is a big barrier to getting people into diagnosis early enough to benefit from these treatments.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Doctors on social media are being harassed and cyberbullied

WSS

Why don't Americans have at

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Venture capital firm's plans to take over Akron hospital face hurdles

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Study gives hint on South Asians’ higher risk of cardiovascular disease

knowledge

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Novavax promises a turnaround & Lilly roils the obesity market

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Supreme Court strikes down use of affirmative action

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Heart attack and stroke risk calculators need revising

Boston competes with Raleigh

Apple is now the first public company to be valued at $3 trillion

Congress must protect the remaining independent doctors

Anesthesiologist group: stop taking Ozempic before surgery

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

knowledge

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Study gives hint on South Asians’ higher risk of cardiovascular disease

Zyn nicotine pouches become unlikely player in latest culture war

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Reconstructing family trees of blood cells may help predict disease

How generative AI ratchets up security threats for health systems

focus

explore

hotspot

entertainment